SELLAS LIFE SCIENCES LIMITED

SELLAS Life Sciences Group identifies ASXL1 mutation as key predictor of SLS009 response in solid cancers, with 67% efficacy observed in ASXL1 mutated cancers vs 0% in non-mutated cancers. ASXL1 mutations were found in colorectal cancer (CRC MSI-H) and non-small cell lung cancer (NSCLC), supporting targeted SLS009 clinical trials.